Dr. David J. Friedman, MD
Hematology (Hematology (Internal Medicine) Physician)
- Medicare participating
At a glance
- Years since graduation
- 55
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 614
Licensed in Texas since 1989, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology (Internal Medicine) Physician primary
TX license H5554 (first issued 1989; active) -
Hematology & Oncology Physician
TX license H5554 (first issued 1989; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Methodist Hospital San Antonio, TX
- Val Verde Regional Medical Center Del Rio, TX
- Uvalde Memorial Hospital Uvalde, TX
- Medina Regional Hospital Hondo, TX
Medical groups
- Texas Oncology PA (1,014 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 614
- Services billed
- 107,604
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 22,345 | 16 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 11,730 | 15 |
| Injection, iron sucrose, 1 mg | 6,100 | 11 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 3,740 | 39 |
| Injection, bortezomib, 0.1 mg | 1,645 | 12 |
| Insertion of needle into vein for collection of blood sample | 1,007 | 288 |
| Blood test, comprehensive group of blood chemicals | 984 | 288 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 896 | 276 |
| Established patient office or other outpatient visit, 30-39 minutes | 768 | 265 |
| Injection, granisetron hydrochloride, 100 mcg | 540 | 15 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Anastrozole Other prescribers in San Antonio, TX | 143 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in San Antonio, TX | 85 |
| Eliquis (apixaban) Other prescribers in San Antonio, TX | 78 |
| Prednisone Other prescribers in San Antonio, TX | 72 |
| Dexamethasone Other prescribers in San Antonio, TX | 69 |
| Xarelto (rivaroxaban) Other prescribers in San Antonio, TX | 66 |
| Acyclovir Other prescribers in San Antonio, TX | 42 |
| Gabapentin Other prescribers in San Antonio, TX | 38 |
| Abiraterone Acetate | 37 |
| Tamoxifen Citrate Other prescribers in San Antonio, TX | 30 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 14 companies reported 52 payments worth $1,462 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $300 |
|---|---|
| E.r. Squibb & Sons, L.l.c. | $231 |
| Regeneron Healthcare Solutions, Inc. | $179 |
| Caris Mpi, Inc. | $137 |
| AbbVie Inc. | $110 |
| Incyte Corporation | $108 |
| Novartis Pharmaceuticals Corporation | $99.01 |
| Merck Sharp & Dohme LLC | $76.22 |
| Food and Beverage | $1,437 |
|---|---|
| Education | $25.70 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC Feb 24, 2025 | Education LYNPARZA · ONCOLOGY · in-kind | $25.70 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $631 in research payments for these studies, mostly to the institutions running them.
- A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Eli Lilly and Company · Active, not recruiting · NCT04965493
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.